组蛋白甲基转移酶G9a抑制剂联合索拉菲尼对肾癌细胞增殖能力的影响

宣广旭, 张晨宇

中国药学杂志 ›› 2019, Vol. 54 ›› Issue (11) : 881-885.

PDF(1978 KB)
PDF(1978 KB)
中国药学杂志 ›› 2019, Vol. 54 ›› Issue (11) : 881-885. DOI: 10.11669/cpj.2019.11.005
论著

组蛋白甲基转移酶G9a抑制剂联合索拉菲尼对肾癌细胞增殖能力的影响

  • 宣广旭1, 张晨宇2*
作者信息 +

Effect of Histone Methyltransferase G9a Inhibitor Combined with Sorafenib on Proliferation of Renal Cell Carcinoma

  • XUAN Guang-xu1, ZHANG Chen-yu2*
Author information +
文章历史 +

摘要

目的 G9a作为组蛋白甲基化转移酶,探究其特异性抑制剂 BIX-01294与经典抗癌药物索拉菲尼联合使用对于肾癌细胞增殖能力的影响。方法 BIX-01294与索拉菲尼各单独或联合作用于A498肾癌细胞时,通过实时荧光定量和蛋白免疫印记法检测G9a的mRNA和蛋白的表达水平,蛋白免疫印记法检测G9a蛋白以及其下游基因H3K9me2的蛋白表达水平,克隆形成实验测定A498细胞的增殖能力,流式细胞术法检测A498细胞的凋亡情况。结果 BIX-01294与索拉菲尼单独使用以及联合用药都能引起G9a蛋白表达水平的下调,同时引起A498细胞增殖能力降低,凋亡水平上调,两者联合使用效果更加明显。结论 BIX-01294 以及索拉菲尼均可引起肾癌细胞G9a mRNA以及蛋白的表达水平下调,两种药物联合使用效果最好,可明显降低细胞的增殖能力,同时细胞凋亡程度更为明显,为肾癌患者的化疗治疗、用药方法以及后续的机制研究提供了全新的参考。

Abstract

OBJECTIVE To investigate the inhibitory effect of combination of histone methylation enzyme G9a specific inhibitor BIX-01294 and sorafenib against renal cell carcinoma. METHODS The mRNA expression level of G9a was detected by RT-PCR, the protein expression level of G9a and its target H3K9me2 were detected by WB in A498 cells. Colony formation assay was used to identify the effect of drug on cell proliferation and migration. Cell apoptosis was detected by flow cytometry. RESULTS G9a expression level can be reduced by BIX-01294 and sorafenib alone and double using of BIX-01294 and sorafenib could down regulate G9a gene expression effectively. Proliferation and migration of A498 cells were decreased, the apoptosis rate was increased present with drugs treatment. CONCLUSION G9a expression level can be down-regulated by either BIX-01294 or sorafenib in renal cancer cells, combined using can get a marked effect. Combining using of BIX-01294 and sorafenib can reduce cell proliferation and migration significantly, can promote cell apoptosis obviously. This research provides us a reference for renal cancer treatment, and the method of administration, the next-step mechanism research.

关键词

组蛋白 / G9a / BIX-01294 / 索拉菲尼 / 肾癌

Key words

histone / G9a / BIX-01294 / sorafenib / kidney cancer

引用本文

导出引用
宣广旭, 张晨宇. 组蛋白甲基转移酶G9a抑制剂联合索拉菲尼对肾癌细胞增殖能力的影响[J]. 中国药学杂志, 2019, 54(11): 881-885 https://doi.org/10.11669/cpj.2019.11.005
XUAN Guang-xu, ZHANG Chen-yu. Effect of Histone Methyltransferase G9a Inhibitor Combined with Sorafenib on Proliferation of Renal Cell Carcinoma[J]. Chinese Pharmaceutical Journal, 2019, 54(11): 881-885 https://doi.org/10.11669/cpj.2019.11.005
中图分类号: R737.11   

参考文献

[1] MCCROSKEY Z, SIM S J, SELZMAN A A, et al. Primary collision tumors of the kidney composed of oncocytoma and papillary renal cell carcinoma: a review [J]. Ann Diagn Pathol, 2017, 8 (29):2932-2936.
[2] MIAO D, MARGOLIS C A, GAO W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma [J]. Science, 2018, 359(6377):801-806.
[3] SHANKAR S R, BAHIRVANI A G, RAO V K, et al. G9a, a multipotent regulator of gene expression [J]. Epigenetics, 2013, 8(1):16-22.
[4] ZHANG J, WANG Y, SHEN Y, et al. G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1 [J]. Theranostics, 2018, 8(10):2884-2895.
[5] CASCIELLO F, WINDLOCH K, GANNON F, et al. Functional role of G9a histone methyltransferase in cancer [J]. Front Immunol, 2015, 9 (25):482-487.
[6] MAYR C, HELM K, JAKAB M, et al. The histone methyltransferase G9a:a new therapeutic target in biliary tract cancer [J]. Hum Pathol, 2018, 2 (72):117-126.
[7] RAO V K, OW J R, SHANKAR S R, et al. G9a promotes proliferation and inhibits cell cycle exit during myogenic differentiation [J]. Nucleic Acids Res, 2016, 44(17):8129-8143.
[8] HUANG Y, ZOU Y, LIN L, et al. Effect of BIX-01294 on proliferation, apoptosis and histone methylation of acute T lymphoblastic leukemia cells [J]. Leuk Res, 2017, 9 (62):34-39.
[9] REN A, QIU Y, CUI H, et al. Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma [J]. Biochem Biophys Res Commun, 2015, 459(1):10-17.
[10] YU H, ZHOU Y G, WANG Y Q. Efficiency and safety of sorafenib in treatment of renal cell carcinoma of Meta-analysis[J]. Chin Pharm J(中国药学杂志), 2014, 49(5):427-430.
[11] WOO S M, SEO S U, MIN K J, et al. BIX-01294 sensitizes renal cancer Caki cells to TRAIL-induced apoptosis through downregulation of survivin expression and upregulation of DR5 expression [J]. Cell Death Discov, 2018, 4(29):1-11.
[12] LARKIN J, GOH X Y, VETTER M, et al. Epigenetic regulation in RCC:opportunities for therapeutic intervention?[J]. Nat Rev Urol, 2012, 9(3):147-155.
[13] TWSSARZ P, KOUZARIDES T. Histone core modifications regulating nucleosome structure and dynamics[J]. Nat Rev Mol Cell Biol, 2014, 15(11):703-708.
[14] STRAHL B D, ALLIS C D. The language of covalent histone modifications [J]. Nature, 2000, 403(6765):41-45.
[15] ZHANG J, HE P, XI Y, et al. Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation [J]. Oncotarget, 2015, 6(5):2917-2927.
[16] KONDO Y, SHEN L, AHMED S, et al. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells [J]. PLoS One, 2008, 3(4):2033-2037.
[17] DAYRYADEL A, BOGDANOVA A, GASSMANN M, et al. Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway[J]. J Cardiothor Surg, 2014, 9(1):8749-8090.
[18] JIANYONG L, JINJING Z, JINGCHENG H, et al. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence[J]. Oncotarget, 2016, 7(27):42598-42607.
[19] STIRZAKER C, SONG J Z, DAVIDSON B, et al. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells [J]. Cancer Res, 2004, 64(11):3871-3877.
[20] COHEN H T, MCGOVERN F J. Renal-cell carcinoma[J]. N Engl J Med, 2005, 353(23):2477-2490.
[21] MOTZER R J, RUSSO P, NANUS D M, et al. Renal cell carcinoma[J]. Curr Probl Cancer, 1997, 21(4):185-232.
[22] ABDELFATAH E, KERNER Z, NANDA N, et al. Epigenetic therapy in gastrointestinal cancer the right combination[J]. Ther Adv Gastroenterol, 2016, 9(4):560-579.
[23] YING W, YAO M A, CHEN N H, et al. Cytotoxicity of solubilizer on nine human tumor cell lines[J]. Chin Pharm J(中国药学杂志), 2013, 48(13):1069-1075.
[24] HUANG X H, MA X D, HUANG Y Q, et al. Effect of BIX-01294 on cell proliferation, apoptosis and histone methylation in Molt-4 line[J]. Chin Pharmacol Bull(中国药理学通报), 2014, 30(10):1392-1396.
[25] PIETROCOLA F, IZZO V, NISO-SANTANO M, et al. Regulation of autophagy by stress-responsive transcription factors[J]. Semin Cancer Biol, 2013, 23(5):310-322.
[26] JIN M, KLIONSKY D J. Regulation of autophagy: modulation of the size and number of autophagosomes[J]. Febs Lett, 2014, 588(15):2457-2463.
[27] FULLGRABE J, KLIONSKY D J, JOSEPH B. The return of the nucleus:transcriptional and epigenetic control of autophagy[J]. Nat Rev Mol Cell Biol, 2014, 15(1):65-74.

基金

国家自然科学基金项目资助(81601962)

PDF(1978 KB)

Accesses

Citation

Detail

段落导航
相关文章

/